复方苦参注射液联合吉西他滨和顺铂治疗非小细胞肺癌的疗效观察

Efficacy of compound matrine injection in combination with gemcitabine and cisplatin chemotherapy in the treatment of patients with advanced non-small-cell lung cancer

目的:观察和比较复方苦参注射液联合吉西他滨和顺铂(GP)的方案与单纯GP方案治疗非小细胞肺癌(NSCLC)的疗效及不良反应。方法:将经病理组织学或细胞学确诊为晚期非小细胞肺癌患者120例作为研究对象,按所接受的方案分为复方苦参注射液联合GP方案组(苦参组)60例及单纯GP方案组(对照组)60例。每例患者至少治疗2周期以上进行疗效评价。结果:苦参组60例:部分缓解(PR)24例,稳定(SD)24例,总有效率为40.00%;对照组60例:部分缓解(PR)22例,稳定(SD)24例。总有效率为36.67%;两组疗效比较差异无显著性。苦参组中37例癌痛患者,治疗后癌痛缓解率为86.49%;对照组中38例癌痛患者治疗后癌痛缓解率为52.63%;差异有显著性(P<0.05)。苦参组白细胞减少的发生率,Ⅲ～Ⅳ度胃肠道反应和肝肾毒性显著少于对照组(P<0.05)。结论:复方苦参注射液能够减少GP方案化疗不良反应,增加患者化疗耐受性。

Objective： To observe and compare the efficacy and toxicity of compound matrine injection in combination with GP regimen （gemcitabine plus cisplatin） and GP regimen in the treatment of patients with ad- vanced non-small-cell lung cancer （NSCLC）. Methods： One hundred and twenty patients with advanced NSCLC diagnosed by pathology or cytology were assigned to receive either compound matrine injection in combination with GP regimen （matrine group,60 cases） or GP regimen alone （control group,60 cases）. After treatment for at least 2 cycles,the curative efficacy was evaluated. Results： The total response rate in matrine group was 40.00% ; 24 had partial remission, and 24 had stable disease. The total response rate in the control group was 36.67% ; 22 had partial remission, and 24 had stable disease. The difference of the overall response rate between the two groups was insignificant. The pain remission rate in matrine group （37 patients with cancer pain） was 86.49% and that in the control group （38 patients with cancer pain） was 52.63% ,showing significant difference between the two groups （ P 〈 0.05 ）. The incidence rates of leucopenia, m - Iv gastrointestinal reaction, and hepatorenal toxicity in matrine group were significantly less than control group （P 〈 0.05）. Conclusion： Compound matrine injection can alleviate the side effects of GP chemotherapy, thus enhance patients＇tolerance to chemotherapy.